At the news
? BULLISHIMPACT 7/10 6-K filed Sep 1, 2026 at 07:04 ET
AstraZeneca announced positive Phase III SANOVO trial results showing Tagrisso plus Orpathys achieved a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) versus Tagrisso alone in first-line MET-overexpressing EGFR-mutated NSCLC. The combination also showed encouraging overall survival benefit. These data extend the all-oral combination into the first-line setting, reinforcing Tagrisso's backbone role and supporting regulatory submissions in China.
- SANOVO Phase III trial met primary endpoint: statistically significant and highly clinically meaningful PFS improvement for Tagrisso + Orpathys vs Tagrisso alone in 1L EGFRm MET-overexpressing NSCLC.
- PFS benefit demonstrated in both high MET (IHC 3+) and ITT (IHC 2+, IHC 3+) populations.
- Overall survival, a secondary endpoint, showed very encouraging clinical benefit; trial continuing follow-up.
- Safety profile consistent with known profiles of each medicine; no new safety findings.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access